Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension

Next Previous
Trial Profile

An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCER
  • Sponsors Daiichi Sankyo Company

Most Recent Events

  • 28 May 2021 Results of pooled analysis of two studies (NCT02318706; DS5565-A-J303 & NCT02318719; DS5565-A-J304) assessing mirogabalin safety and efficacy, published in the Clinical Therapeutics.
  • 08 Jan 2019 According to a Daiichi Sankyo Company media release, based on the results of REDUCER and NEUCOURSE clinical trials, the company has received marketing approval in Japan for Tarlige Tablets 2.5 mg, 5 mg, 10 mg, 15 mg for the treatment of peripheral neuropathic pain (PNP).
  • 01 Aug 2018 Results of pool data from four trials, were published in the Clinical Pharmacology in Drug Development.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top